{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:59:12Z","timestamp":1783115952971,"version":"3.54.6"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antistaphylococcal penicillin (ASP) is the first-line therapy for MSSA bloodstream infection (BSI), with cefazolin as an alternative. However, ASPs are associated with a high risk of acute kidney injury (AKI) and overexposure. We implemented a kidney-sparing protocol based on: (i) systematic use of cefazolin in patients with creatinine clearance of &amp;lt;60\u2005mL\/min or any risk factor for AKI; and (ii) reduced ASP dose (75\u2013100\u2005mg\/kg\/day) with therapeutic drug monitoring.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We compared all episodes of MSSA BSI in adults admitted during the 15\u2005months before (control period) and the 12\u2005months after (optimization period) protocol implementation. Primary outcome was sterile blood cultures by Day 3. Secondary outcomes included AKI, dialysis, MSSA BSI relapses, and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 100 patients in the control group and 104 in the optimization group. Baseline characteristics were similar in both groups, with a mean\u200a\u00b1\u200aSD age of 73\u200a\u00b1\u200a20\u2005years, male predominance (73%), and high prevalence of chronic kidney disease (80%) and diabetes (31%). Initial treatment was ASP (cloxacillin) in 80\/100 (80%) patients in the control group, versus 24\/104 (23%) in the optimization group (P\u200a&amp;lt;\u200a0.001). Day 3 sterile blood cultures, and Day 30 mortality remained similar (respectively 95% versus 93%, and 21% versus 24%; not significant). AKI and dialysis requirements were less frequent during the optimization period, respectively 37% versus 56% (P\u200a=\u200a0.045), and 1% versus 8% (P\u200a=\u200a0.017).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A kidney-sparing protocol for MSSA BSI based on systematic use of cefazolin in patients with AKI risk factor, and lower ASP doses, was associated with similar efficacy and lower risk of AKI and dialysis requirements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf062","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:42:42Z","timestamp":1741124562000},"page":"1261-1268","source":"Crossref","is-referenced-by-count":1,"title":["Impact of a kidney-sparing protocol for the treatment of methicillin-susceptible <i>Staphylococcus aureus<\/i> bloodstream infections (CLOXECO): a quasi-experimental study"],"prefix":"10.1093","volume":"80","author":[{"given":"Philippine","family":"Babin","sequence":"first","affiliation":[{"name":"Service de n\u00e9phrologie, H\u00f4pital Pontchaillou, rue le Guilloux , CHU Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Delbove","sequence":"additional","affiliation":[{"name":"Service de r\u00e9animation m\u00e9dicale, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gousseff","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses et m\u00e9decine interne, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Gouin","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Crabol","sequence":"additional","affiliation":[{"name":"Service de maladies infectieuses et m\u00e9decine interne, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauriac","family":"Akoha","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cady","sequence":"additional","affiliation":[{"name":"Service de biologie m\u00e9dicale, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-3629","authenticated-orcid":false,"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"Pharmacologie Clinique, H\u00f4pital Pontchaillou, rue le Guilloux , CHU Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3617-5411","authenticated-orcid":false,"given":"Pierre","family":"Tattevin","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie, H\u00f4pital Pontchaillou, rue le Guilloux , CHU Rennes ,","place":["France"]},{"name":"Maladies Infectieuses et R\u00e9animation M\u00e9dicale, H\u00f4pital Pontchaillou, rue le Guilloux , CHU Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugoline","family":"Boulay","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie, Centre Hospitalier Bretagne Atlantique, Boulevard G\u00e9n\u00e9ral Maurice Guillaudot , Vannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2025050205523900300_dkaf062-B1","doi-asserted-by":"publisher","first-page":"e0242921","DOI":"10.1128\/jcm.02429-21","article-title":"Prevalence and mortality associated with bloodstream organisms: a population-wide retrospective cohort study","volume":"60","author":"Verway","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025050205523900300_dkaf062-B2","doi-asserted-by":"publisher","first-page":"2002094","DOI":"10.2807\/1560-7917.ES.2021.26.46.2002094","article-title":"Staphylococcus aureus bloodstream infections: diverging trends of meticillin-resistant and meticillin-susceptible isolates, EU\/EEA, 2005 to 2018","volume":"26","author":"Gagliotti","year":"2021","journal-title":"Euro Surveill"},{"key":"2025050205523900300_dkaf062-B3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025050205523900300_dkaf062-B4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.3390\/jcm10122603","article-title":"Incidence and risk factors for acute kidney injury during the treatment of methicillin-sensitive Staphylococcus aureus infections with cloxacillin based antibiotic regimens: a French retrospective study","volume":"10","author":"Crochette","year":"2021","journal-title":"J Clin Med"},{"key":"2025050205523900300_dkaf062-B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13613-017-0255-8","article-title":"Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects","volume":"7","author":"Neuville","year":"2017","journal-title":"Ann Intensive Care"},{"key":"2025050205523900300_dkaf062-B6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000185306","article-title":"Interstitial nephritis induced by cloxacillin","volume":"51","author":"Grimm","year":"1989","journal-title":"Nephron"},{"key":"2025050205523900300_dkaf062-B7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijantimicag.2018.04.007","article-title":"Acute kidney injury during treatment with high-dose cloxacillin: a report of 23 cases and literature review","volume":"52","author":"Lavergne","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205523900300_dkaf062-B8","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"2025050205523900300_dkaf062-B9","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205523900300_dkaf062-B10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025050205523900300_dkaf062-B11","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/jac\/dkt254","article-title":"Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals","volume":"68","author":"Rincon","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025050205523900300_dkaf062-B12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2025050205523900300_dkaf062-B13","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1128\/AAC.00533-11","article-title":"Simultaneous determination of 12 \u03b2-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring","volume":"55","author":"Verdier","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205523900300_dkaf062-B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1056\/NEJMp2028243","article-title":"In search of a better equation\u2014performance and equity in estimates of kidney function","volume":"384","author":"Diao","year":"2021","journal-title":"N Engl J Med"},{"key":"2025050205523900300_dkaf062-B15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.ki.5002743","article-title":"The RIFLE criteria and mortality in acute kidney injury: a systematic review","volume":"73","author":"Ricci","year":"2008","journal-title":"Kidney Int"},{"key":"2025050205523900300_dkaf062-B16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025050205523900300_dkaf062-B17","doi-asserted-by":"publisher","first-page":"e01562-20","DOI":"10.1128\/AAC.01562-20","article-title":"A population pharmacokinetic analysis of continuous infusion of cloxacillin during Staphylococcus aureus bone and joint infections","volume":"64","author":"Courjon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205523900300_dkaf062-B18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/jac\/dkad030","article-title":"Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis","volume":"78","author":"Bellouard","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025050205523900300_dkaf062-B19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025050205523900300_dkaf062-B20","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/jac\/dky259","article-title":"Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins","volume":"73","author":"Bidell","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025050205523900300_dkaf062-B21","doi-asserted-by":"publisher","first-page":"e023151","DOI":"10.1136\/bmjopen-2018-023151","article-title":"Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial","volume":"8","author":"Burdet","year":"2018","journal-title":"BMJ Open"},{"key":"2025050205523900300_dkaf062-B22","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus Network Adaptive Platform trial protocol: new tools for an old foe","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025050205523900300_dkaf062-B23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/1120009X.2017.1296916","article-title":"Risk factors for acute kidney injury associated with the treatment of bacterial endocarditis at a tertiary academic medical center","volume":"29","author":"Ritchie","year":"2017","journal-title":"J Chemother"},{"key":"2025050205523900300_dkaf062-B24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"Van Hal","year":"2012","journal-title":"Clin Microbiol Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1261\/62201883\/dkaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1261\/62201883\/dkaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:52:43Z","timestamp":1746179563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1261\/8045732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf062","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,28]]}}}